Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 24011-24031

  Yang, Guang Wei ^a   Jiang, Jin Song ^a   Lu, Wei Qin ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Akt; Angiogenesis; Ferulic acid; FGFR1; Melanoma

Indexed keywords

AURORA A KINASE; CD135 ANTIGEN; CD31 ANTIGEN; COLLAGEN TYPE 4; CYCLIN DEPENDENT KINASE 2; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FERULIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B KINASE BETA; JANUS KINASE; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COUMARIC ACID; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 1; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHICKEN; CHORIOALLANTOIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA CELL; MOUSE; MTT ASSAY; NONHUMAN; RADIOMETRY; RAT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; WESTERN BLOTTING; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; MELANOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; COUMARIC ACIDS; ENZYME ACTIVATION; FEMALE; FIBROBLAST GROWTH FACTOR 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944061935     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161024011     Document Type: Article

References (37)

1. Tchernev, G.; Chokoeva, A.A.; Wollina, U.; Patterson, J.W.; Lotti, T. Melanoma imitators-how to prevent the aggressive approach? J. Biol. Regul. Homeost. Agents 2015, 29, 75-80.
2. Welti, J.; Loges, S.; Dimmeler, S.; Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Investig. 2013, 123, 3190-3200.
3. Meierjohann, S. Hypoxia-independent drivers of melanoma angiogenesis. Front. Oncol. 2015, 5, 102, doi:10.3389/fonc.2015.00102.
4. Lee, S.H.; Koo, B.S.; Park, S.Y.; Kim, Y.M. Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. Mol. Med. Rep. 2015, 12, 2777-2783.
5. De Brot, S.; Ntekim, A.; Cardenas, R.; James, V.; Allegrucci, C.; Heery, D.M.; Bates, D.O.; Ødum, N.; Persson, J.L.; Mongan, N.P. Regulation of vascular endothelial growth factor in prostate cancer. Endocr. Relat. Cancer 2015, 22, R107-R123.
6. Alfaidy, N.; Hoffmann, P.; Boufettal, H.; Samouh, N.; Aboussaouira, T.; Benharouga, M.; Feige, J.J.; Brouillet, S. The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis. Biomed. Res. Int. 2014, 2014, 451906, doi:10.1155/2014/451906.
7. Katoh, M.; Katoh, M. Cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol. Ther. 2006, 5, 1059-1064.
8. Chen, G.J.; Weylie, B, Hu, C.; Zhu, J.; Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem. 2007, 101, 1492-1504.
9. Vara, J.A.F.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; González-Barón, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.
10. Lin, Y.; Wang, X.; Jin, H. EGFR-TKI resistance in NSCLC patients: Mechanisms and strategies. Am. J. Cancer Res. 2014, 4, 411-435.
11. Choi, Y.E.; Park, E. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. Biochem. Biophys. Res. Commun. 2015, 458, 520-524.
12. Peng, C.C.; Chyau, C.C.; Wang, H.E.; Chang, C.H.; Chen, K.C.; Chou, K.Y.; Peng, R.Y. Cytotoxicity of ferulic acid on T24 cell line differentiated by different microenvironments. Biomed. Res. Int. 2013, 2013, 579859, doi:10.1155/2013/579859.
13. Pan, M.H.; Ho, C.T. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 2008, 37, 2558-2574.
14. Kim, H.J.; Ryu, K.; Kang, J.H.; Choi, A.J.; Kim, T.I.; Oh, J.M. Anticancer activity of ferulic acid-inorganic nanohybrids synthesized via two different hybridization routes, reconstruction and exfoliation-reassembly. Sci. World J. 2013, 2013, 421967, doi:10.1155/2013/421967.
15. Lin, C.M.; Chiu, J.H.; Wu, I.H.; Wang, B.W.; Pan, C.M.; Chen, Y.H. Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1α. J. Nutr. Biochem. 2010, 21, 627-633.
16. Wang, J.; Yuan, Z.; Zhao, H.; Ju, D.; Chen, Y.; Chen, X.; Zhang, J. Ferulic acid promotes endothelial cells proliferation through up-regulating cyclin D1 and VEGF. J. Ethnopharmacol. 2011, 137, 992-997.
17. Hou, Y.; Yang, J.; Zhao, G.; Yuan, Y. Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. J. Cell. Biochem. 2004, 93, 1203-1209.
18. Dol-Gleizes, F.; Delesque-Touchard, N.; Marès, A.M.; Nestor, A.L.; Schaeffer, P.; Bono, F. A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE 2013, 8, e80027.
19. Kim, J.K.; Kim, J.Y.; Kim, H.J.; Park, K.G.; Harris, R.A.; Cho, W.J.; Lee, J.T.; Lee, I.K. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PLoS ONE 2013, 8, e80391.
20. Mbengue, A.; Bhattacharjee, S.; Pandharkar, T.; Liu, H.; Estiu, G.; Stahelin, R.V.; Rizk, S.S.; Njimoh, D.L.; Ryan, Y.; Chotivanich, K.; et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 2015, 520, 683-687.
21. Salt, M.B.; Bandyopadhyay, S.; McCormick, F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014, 4, 186-199.
22. Katoh, M.; Nakagama, H. FGF receptors: Cancer biology and therapeutics. Med. Res. Rev. 2014, 34, 280-300.
23. Rapisarda, A.; Melillo, G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114, 237-267.
24. Dey, J.H.; Bianchi, F.; Voshol, J.; Bonenfant, D.; Oakeley, E.J.; Hynes, N.E. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010, 70, 4151-4162.
25. Yuan, G.; Yan, S.; Xue, H.; Zhang, P.; Sun, J.; Li, G. JSI-124 suppresses invasion and angiogenesis of glioblastoma cells in vitro. PLoS ONE 2015, 10, e0118894.
26. Lau, M.T.; So, W.K.; Leung, P.C. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS ONE 2013, 8, e59083.
27. Zhang, L.; Xie, Q.; Shan, S.J.; Tabor, M.K.; Junkins-Hopkins, J.M. Reduced expression of RECK protein may help differentiate cutaneous malignant melanoma from melanocytic nevus. Anticancer Res. 2015, 35, 3185-3191.
28. Gong, M.; Yang, J.T.; Liu, Y.Q.; Tang, L.H.; Wang, Y.; Wang, L.J.; Zhang, F.J.; Yan, M. Irradiation can selectively kill tumor cells while preserving erythrocyte viability in a co-culture system. PLoS ONE 2015, 10, e0127181.
29. Adaramoye, O.; Erguen, B.; Oyebode, O.; Nitzsche, B.; Höpfner, M.; Jung, K.; Rabien, A. Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells. J. Integr. Med. 2015, 13, 185-193.
30. Khoury, N.; El-Hayek, S.; Tarras, O.; El-Sabban, M.; El-Sibai, M.; Rizk, S. Kefir exhibits anti-proliferative and pro-apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion. Int. J. Oncol. 2014, 45, 2117-2127.
31. Liao, X.; Zhou, X.; Mak, N.K.; Leung, K.N. Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway. PLoS ONE 2013, 8, e82294.
32. Otjacques, E.; Binsfeld, M.; Rocks, N.; Blacher, S.; Vanderkerken, K.; Noel, A.; Beguin, Y.; Cataldo, D.; Caers, J. Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. PLoS ONE 2013, 8, e62818.
33. Kue, C.S.; Tan, K.Y.; Lam, M.L.; Lee, H.B. Chick embryo chorioallantoic membrane (CAM): An alternative predictive model in acute toxicological studies for anti-cancer drugs. Exp. Anim. 2015, 64, 129-138.
34. Saraswati, S.; Kanaujia, P.K.; Kumar, S.; Kumar, R.; Alhaider, A.A. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Mol. Cancer 2013, 12, 82, doi:10.1186/1476-4598-12-82.
35. Campton, D.E.; Ramirez, A.B.; Nordberg, J.J.; Drovetto, N.; Clein, A.C.; Varshavskaya, P.; Friemel, B.H.; Quarre, S.; Breman, A.; Dorschner, M.; et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer 2015, 15, 360, doi:10.1186/s12885-015-1383-x.
36. Yeh, M.Y.; Wu, M.F.; Shang, H.S.; Chang, J.B.; Shih, Y.L.; Chen, Y.L.; Hung, H.F.; Lu, H.F.; Yeh, C.; Wood, W.G.; et al. Effects of chitosan on xenograft models of melanoma in C57BL/6 mice and hepatoma formation in SCID mice. Anticancer Res. 2013, 33, 4867-4873.
37. Theophanous, E.; Petraki, C.; Scorilas, A.; Komborozos, V.; Veloudis, G.; Varga, J.L.; Zarandi, M.; Schally, A.V.; Koutsilieris, M. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol. Med. 2009, 15, 242-247.